Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 13;12:6154. doi: 10.1038/s41598-022-09964-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

PD-L1xCD3 BiTE interacted to CD3 and activated T cells (A) CD3 positive lymphocyte population demonstrated as histogram. (B and C) The histogram showed the ability of mBiTE and sBiTE to directly bind to CD3 on T cells. The bar graph represents the % positive cells detected by anti-Fab mAb. (D and E) The histogram and bar graph showed % positive cells detected by anti-CD3 mAb after blocking with mBiTE and sBiTE (% blocking). (F and G) The histogram and bar graph showed % CD25 positive cells after 48 h of mBiTE and sBiTE treatment. (H) The histogram and bar graph demonstrated the activity of mBiTE and sBiTE to promote T cell proliferation after Day2-Day4 after treatment accessed by CFSE proliferation assay. Data are presented as the mean ± standard error or the mean (SEM) (*p < 0.05, **p < 0.01, ***p < 0.001).